University of Birmingham's Phase 2 Trial Compares Reduced-Intensity Conditioning Regimens for Adult ALL Patients Prior to Transplantation, Evaluating Sanofi's Alemtuzumab and Others
Clinical Background and Research Objectives
Reduced-Intensity Conditioning (RIC) regimens, used as pre-transplant treatment for adult patients with Acute Lymphoblastic Leukemia (ALL), are essential for improving patient survival. The University of Birmingham-led Phase 2 ALL-RIC clinical trial is designed to compare existing standard chemotherapy with a novel radiation-based regimen to reduce the risk of relapse in older patients. The existing treatment has achieved a 2-year survival rate of 60%, but still faces limitations due to high relapse rates in patients with residual Minimal Residual Disease (MRD). Therefore, the development of new pre-treatment combinations that can improve survival and suppress relapse is considered a significant turning point in addressing the unmet needs of older leukemia patients.
Patient Population and Treatment Regimen Design
This study (NCT03821610) is a randomized trial involving 242 adult ALL patients aged 40 to 70 who are in Complete Remission (CR). The control group will receive a standard RIC regimen consisting of Sanofi's Alemtuzumab, Fludarabine, and Melphalan from Apotex. The experimental group will receive a low-dose Total Body Irradiation (TBI) of 8Gy in combination with Cyclophosphamide from Bristol Myers Squibb (BMY) and Mesna from Baxter. By comparing the chemotherapy-alone group with the radiation-combined group, the study aims to establish an optimized, low-toxicity, high-efficacy pre-treatment regimen for older patients.
Clinical Trial Status and Safety Assessment
The clinical trial was initiated in November 2018 and completed the observation for the primary endpoint, 2-year Disease-Free Survival (DFS), on October 31, 2025. The study's secondary endpoints include Overall Survival (OS) and Non-Relapse Mortality (NRM), as well as the incidence of acute and chronic Graft-versus-Host Disease (GvHD), indicating comprehensive safety assessments. The final completion of the clinical trial is expected in November 2027, which will likely be used as a regulatory submission with long-term survival data. As an Investigator-Initiated Trial (IIT), there are no immediate commercial deal values, but it is attracting attention from academia and industry due to its potential to lead to revisions in pre-transplant guidelines.
Treatment Market and Competitive Landscape
The global ALL treatment market is currently estimated at approximately $3.65 billion to $5.27 billion as of 2025, and is projected to expand to approximately $11 billion by 2035. In the market for RIC standard regimens for older ALL patients, therapies such as Fludarabine+Melphalan (FMA) and Fludarabine+Busulfan (Flu/Bu) are competing. Sanofi's Alemtuzumab (Campath) has been approved by the FDA since 2001 and has been widely used in leukemia treatment, but concerns remain regarding the risk of opportunistic infections due to post-transplant immunosuppression. Therefore, this trial, which aims to reduce the dose of Total Body Irradiation (TBI) and optimize targeted chemotherapy to minimize toxicity, focuses on demonstrating superior safety compared to the Standard of Care (SoC).
This Phase 2 investigator-initiated trial (ALL-RIC) evaluates whether a low-dose Total Body Irradiation (TBI) regimen (8Gy) combined with Cyclophosphamide improves 2-year Disease-Free Survival (DFS) compared to the standard Fludarabine+Melphalan regimen in adult ALL patients aged 40-70 undergoing pre-transplant Reduced-Intensity Conditioning (RIC). In the global ALL treatment market, estimated at approximately $3.65 billion in 2025, the increasing proportion of older patients is driving the need for personalized, low-toxicity pre-treatment regimens, which will be a key factor in long-term market growth. Overcoming the limitations of existing immunosuppressive antibody therapies such as Sanofi's Alemtuzumab (Campath) and reducing side effects such as Graft-versus-Host Disease (GvHD) will require portfolio diversification by manufacturers of Total Body Irradiation equipment and generic anti-cancer drugs. With the primary endpoint observation achieved in October 2025 and final completion expected in November 2027, the long-term survival data from this trial will likely lead to revisions in the guidelines for hematopoietic stem cell transplantation in older ALL patients, which will in turn promote the expanded use of supportive drugs.
Source: ClinicalTrials.gov (api_ct)